Protocol Number: GR40549
Principal Investigator: Thomas Aaberg, Jr., M.D.
The purpose of this study is to find out the long-term safety and tolerability, and the effects of the ocular (eye) implant on you and your wet AMD when it delivers a dose of ranibizumab. The ocular implant releases ranibizumab continuously (without stopping) for a long period of time into the back of your eye and it can be refilled by the study doctor. Because the implant releases ranibizumab over time, you may not need treatment as often. The implant is intended to remain life-long in the eye unless removed for medical reasons. The ocular implant together with the ranibizumab and the devices used to fill and refill the implant are approved in the United States for the treatment of neovascular AMD (wet AMD). However, in countries other than the United States, the ocular implant, the devices used to fill and refill the implant, and/or ranibizumab may not yet be approved for the treatment of wet AMD and are considered an experimental drug and devices that will only be given to the participant in this research study.